Yang Xia, Qiang Xiaoming, Li Yan, Luo Li, Xu Rui, Zheng Yunxiaozhu, Cao Zhongcheng, Tan Zhenghuai, Deng Yong
Department of Medicinal Chemistry, Key Laboratory of Drug Targeting and Drug Delivery System of the Education Ministry, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
Institute of Traditional Chinese Medicine Pharmacology and Toxicology, Sichuan Academy of Chinese Medicine Sciences, Chengdu 610041, China.
Bioorg Chem. 2017 Apr;71:305-314. doi: 10.1016/j.bioorg.2017.02.016. Epub 2017 Feb 28.
A series of pyridoxine-resveratrol hybrids Mannich base derivatives as multifunctional agents have been designed, synthesized and evaluated for cholinesterase (ChE) and monoamine oxidase (MAO) inhibitory activity. To further explore the multifunctional properties of the new derivatives, their antioxidant activities and metal-chelating properties were also tested. The results showed that most of these compounds could selectively inhibit acetylcholinesterase (AChE) and MAO-B. Among them, compounds 7d and 8b exhibited the highest potency for AChE inhibition with IC values of 2.11μM and 1.56μM, respectively, and compound 7e exhibited the highest MAO-B inhibition with an IC value of 2.68μM. The inhibition kinetic analysis revealed that compound 7d showed a mixed-type inhibition, binding simultaneously to the CAS and PAS of AChE. Molecular modeling study was also performed to investigate the binding mode of these hybrids with MAO-B. In addition, all target compounds displayed good antioxidant and metal-chelating properties. Taken together, these preliminary findings can be a new starting point for further development of multifunctional agents for Alzheimer's disease.
设计、合成并评估了一系列作为多功能药剂的吡哆醇-白藜芦醇杂化曼尼希碱衍生物的胆碱酯酶(ChE)和单胺氧化酶(MAO)抑制活性。为了进一步探索新衍生物的多功能特性,还测试了它们的抗氧化活性和金属螯合特性。结果表明,这些化合物中的大多数能够选择性抑制乙酰胆碱酯酶(AChE)和MAO-B。其中,化合物7d和8b对AChE抑制表现出最高效力,IC值分别为2.11μM和1.56μM,化合物7e对MAO-B抑制表现出最高效力,IC值为2.68μM。抑制动力学分析表明,化合物7d表现出混合型抑制,同时与AChE的催化活性位点(CAS)和外周活性位点(PAS)结合。还进行了分子模拟研究以探究这些杂化物与MAO-B的结合模式。此外,所有目标化合物均表现出良好的抗氧化和金属螯合特性。综上所述,这些初步研究结果可为进一步开发用于阿尔茨海默病的多功能药剂提供新的起点。